Daria J. Hazuda

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

2

Total Citations

12

H-Index

2

About

Daria J. Hazuda is a pioneering researcher in the fields of HIV latency reversal and antibacterial pharmacodynamics. Her major contributions center on developing innovative automated platforms to study drug efficacy and resistance. In her work on HIV, she has advanced the understanding of latency reversal by histone deacetylase inhibitors (HDACis), creating automated pharmacokinetic/pharmacodynamic models to evaluate novel compounds aimed at eradicating the latent viral reservoir—a critical barrier to curing chronic HIV infection. This research, cited over 6 times, highlights her impact on designing strategies to move beyond suppressive antiretroviral therapy. Additionally, Hazuda has developed a fully automated platform for agar-based measurement of viable bacterial growth, revolutionizing dynamic in vitro antibacterial studies. This system reduces labor-intensive sampling while providing crucial insights into effective dosing regimens before in vivo translation. Her work bridges computational automation with biological complexity, offering scalable solutions for both HIV cure research and antibiotic development. Hazuda’s achievements underscore her role in advancing precision medicine and high-throughput methodologies, making her a notable figure in infectious disease pharmacology.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
6 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago